Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Nov 6, 2018
Grant Date -
May 6, 2010
app pub date -
Dec 29, 2009
filing date -
Jun 27, 2003
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully